CorMedix Reaffirms FY26 Total Sales Guidance Of $325M-$345M; Anticipates That The DefenCath Add-On Will Decline Sequentially In Q2 2027, With A QoQ Increase In Q3 And/Or Q4
CorMedix announces unaudited cash and cash equivalents on hand as of September 30, 2026 of approximately $355 million. CorMedix reaffirms its August 2026 total revenue guidance of between $325 million and $345 million
CorMedix says its full year sales will be between 325 and 345 million dollars. The company expects one product to dip in early 2027, then bounce back later.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.